Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics

Apellis Pharmaceuticals, Inc. (APLS): $47.53

0.02 (+0.04%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add APLS to Watchlist
Sign Up

APLS Price/Volume Stats

Current price $47.53 52-week high $94.75
Prev. close $47.51 52-week low $19.83
Day low $46.53 Volume 1,179,300
Day high $48.19 Avg. volume 1,500,053
50-day MA $59.89 Dividend yield N/A
200-day MA $52.39 Market Cap 5.73B

APLS Stock Price Chart Interactive Chart >


Apellis Pharmaceuticals, Inc. (APLS) Company Bio


Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.


APLS Latest News Stream


Event/Time News Detail
Loading, please wait...

APLS Latest Social Stream


Loading social stream, please wait...

View Full APLS Social Stream

Latest APLS News From Around the Web

Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the even

Yahoo | December 28, 2023

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. In the latest market developments on December 18, Asian stocks experienced a notable decline, […]

Yahoo | December 18, 2023

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Yahoo | December 15, 2023

Apellis Crashes 17% As It Stares Down A Likely European Rejection

Apellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line.

Yahoo | December 14, 2023

UPDATE 1-Apellis says EU regulator panel may not back its eye disease drug

Apellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for its drug to treat a chronic eye disease, sending its shares down more than 14% in premarket trading. The company said it was informed on Wednesday that the panel may vote against the drug, a form of pegcetacoplan directly injected in the back of the eye, at the next meeting on Jan. 22-25.

Yahoo | December 14, 2023

Read More 'APLS' Stories Here

APLS Price Returns

1-mo -14.19%
3-mo -27.38%
6-mo -2.92%
1-year -44.89%
3-year 3.17%
5-year 145.89%
YTD -20.60%
2023 15.76%
2022 9.37%
2021 -17.34%
2020 86.81%
2019 132.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!